RADAR

RADAR
RADAR provides health professionals with timely, independent, evidence-based information on new drugs and medical tests and changes to listings on the Pharmaceutical Benefits Scheme and Medicare Benefits Schedule.
All articles
Latest full reviews

Vericiguat (Verquvo) for persistent chronic heart failure with LVEF < 45%

Vericiguat (Verquvo) for persistent chronic heart failure with LVEF < 45%
  • 30 November 2022

Vericiguat is a new medicine belonging to a novel class of medicines called soluble guanylate cyclase (sGC) stimulators.

Molnupiravir (Lagevrio) for mild-to-moderate COVID-19

Molnupiravir (Lagevrio) for mild-to-moderate COVID-19

Molnupiravir (Lagevrio) for mild-to-moderate COVID-19

  • 7 March 2022
  • 10 minutes

Dapagliflozin (Forxiga) for heart failure with reduced ejection fraction (LVEF ≤ 40%)

Dapagliflozin (Forxiga) for heart failure with reduced ejection fraction (LVEF ≤ 40%)

Dapagliflozin (Forxiga) for heart failure with reduced ejection fraction (LVEF ≤ 40%)

  • 27 December 2021

Palliative care: New, amended and deleted PBS items

Palliative care: New, amended and deleted PBS items

Palliative care: New, amended and deleted PBS items

  • 15 June 2021
  • 8 minutes

Opioids: New and amended PBS listings

Opioids: New and amended PBS listings

Opioids: New and amended PBS listings

  • 18 June 2020
  • 15 min read

Risperidone: Revised PBS restrictions for behavioural and psychological symptoms of dementia

Risperidone: Revised PBS restrictions for behavioural and psychological symptoms of dementia

Risperidone: Revised PBS restrictions for behavioural and psychological symptoms of dementia

  • 19 March 2020
  • 13 min read

Naloxone nasal spray (Nyxoid) for opioid overdose

Naloxone nasal spray (Nyxoid) for opioid overdose

Naloxone nasal spray (Nyxoid) for opioid overdose

  • 15 January 2020
Wrap up
COVID-19 oral antiviral PBS eligibility criteria update – November 2022
  • 18 January 2023
September 2022 New listing
  • 16 September 2022
PBS listing for hydroxychloroquine updated (2022)
  • 4 May 2022
February 2022 New listings
  • 7 February 2022
Latest in brief
Changes to COVID-19 oral antiviral (Paxlovid) PBS eligibility criteria – April 2023
  • 27 April 2023
Revised PBS restrictions for fluticasone propionate 50 microgram per dose inhalers
  • 1 April 2023
Dapagliflozin for chronic kidney disease
  • 1 September 2022
Changes to COVID-19 oral antiviral PBS eligibility criteria – July 2022
  • 13 July 2022